MassMutual Ventures Southeast Asia, Alibaba Entrepreneurs Fund and Wavemaker Partners have invested in knowledge-as-a-service (KaaS) company Lynk while gene therapy biopharmaceutical firm Hui-Gene has gathered over 100 million yuan ($14 million) in its Series A funding round.
Alibaba Entrepreneurs Fund backs global KaaS platform Lynk
Lynk, a global network that connects world-class experts to users, has raised an undisclosed round of funding led by MassMutual Ventures Southeast Asia, according to a company statement.
Existing investors Alibaba Entrepreneurs Fund, an initiative of Chinese internet giant Alibaba, and Wavemaker Partners, also joined the round.
Since 2015, Lynk has created a KaaS-based technology platform to provide solutions on natural language processing, conversational AI analytics and machine learning. Through the platform, enterprises can approach experts in any sector to gain market insights.
Lynk serves over 14 languages in different time zones with offices in Singapore, Hong Kong, New York, and Mumbai.
Hui-Gene Therapeutics raises over $14m in Series A round
Chinese biopharma firm Hui-Gene Therapeutics has gathered over 100 million yuan ($14 million) in its Series A round led by CD Capital, per a company statement on Monday.
The current round also saw participation from WuXi AppTec, Huimei Healthcare Management – a joint venture by Hillhouse Capital and Mayo Clinic, Alwin Capital, and existing investor Sherpa VC.
Established in 2018, Shanghai-headquartered Hui-Gene is focused on R&D for single-gene disorders and has developed pilot pipes in neurodegenerative diseases, vision disorders, among others.
Hui-Gene plans to facilitate its pipeline, build a clinical-stage team and scale a GMP-level manufacturing factory.